Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.
You may also be interested in...
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.
The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.